MedPath

Confo Therapeutics

🇧🇪Belgium
Ownership
-
Employees
-
Market Cap
-
Website

Safety and Tolerability of CFTX-1554 in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2022-03-02
Last Posted Date
2023-09-05
Lead Sponsor
Confo Therapeutics
Target Recruit Count
97
Registration Number
NCT05260658
Locations
🇳🇱

PRA Health Sciences, Groningen, Netherlands

© Copyright 2025. All Rights Reserved by MedPath